Can a Family Member Be a Hematopoietic Stem Cell Donor? (2026 Update)

Yes. Siblings are considered first, and if there is no full match, parents or children can serve as donors through a haploidentical (half-matched) transplant. Beyond that, unrelated donors and cord blood are also available options.

Key Points

• For allogeneic transplants, donors are searched for in this order: siblings → haploidentical family members (parents/children) → unrelated donors → cord blood.
• A haploidentical transplant uses a family member (parent or child) who is only a half-match rather than a full match, and Korea has substantial accumulated experience with this approach.
• Allogeneic transplant works because the donor's immune cells attack any remaining cancer cells, but that same immunity can attack the patient's own body, causing graft-versus-host disease (GVHD), which is managed with immunosuppressants.
• Engraftment, when the new cells take hold, typically takes 2 to 4 weeks, during which the patient stays in a sterile isolation room.
• The remote review (pre-arrival review) fee is KRW 1,000,000 (about US$730), and this amount is deducted from treatment costs if the patient signs a treatment contract (based on National Cancer Center Korea, NCCN patient guidelines, and Medical Korea).

If Family Members Aren't a Full Match, Are There No Options Left?

• No, there are still options. Even if siblings aren't a tissue match, alternatives remain: a haploidentical transplant using a parent or child, a search for an unrelated donor, or cord blood.
• A haploidentical transplant proceeds with only a half-match rather than a full match, and Korea's accumulated experience with this method helps broaden the pool of potential donors.
• Which path is actually feasible depends on the type of disease, the patient's age, and the urgency of treatment, so individual case review is necessary.

What Is the Step-by-Step Process for Hematopoietic Stem Cell Transplant?

1. Step 1: Over 1 to 2 weeks, staging tests are performed along with checks of heart, lung, liver, and kidney function and infection screening. For allogeneic transplants, the donor's tissue compatibility (HLA) testing and health screening are conducted in parallel.
2. Step 2: A central venous catheter is placed for chemotherapy and transfusions, and the patient undergoes roughly one week of high-dose conditioning chemotherapy to clear out the diseased bone marrow.
3. Step 3: On the scheduled day, the hematopoietic stem cells are infused intravenously. The transplant itself is not surgery but more like a transfusion, taking only a few tens of minutes.
4. Step 4: The patient spends 2 to 4 weeks in a sterile isolation room until engraftment is confirmed. Fever, mouth sores, and low blood counts are common and are managed with transfusions and antibiotics.
5. Step 5: After engraftment is confirmed, the patient is discharged but does not return home immediately—instead, they stay within walking distance of the hospital for frequent outpatient visits. Hospitalization typically runs 3 to 6 weeks, with a total stay of 6 to 8 weeks, and for allogeneic transplants, close monitoring often continues for around 100 days post-transplant.

What Should Be Kept in Mind When a Family Member Is the Donor?

• In allogeneic transplant, graft-versus-host disease (GVHD) can occur, presenting as skin rash, diarrhea, elevated liver enzymes, and dryness of the eyes and mouth. It can appear acutely early on or emerge as a chronic form months later.
• Severity ranges from mild to serious, so early detection and management are important, and patients are instructed to monitor these changes daily and report them immediately.
• If a family member is a candidate donor, HLA testing and health records should be prepared alongside the patient's own workup, and viral reactivation is also checked regularly while the patient is on immunosuppressants.

FAQ — Can Parents or Children Also Be Donors?

Yes, parents and children can serve as haploidentical donors, matching only half the tissue type. This approach is considered when no fully matched sibling is available, and Korea's accumulated experience with this method helps reduce cases where treatment is delayed due to an inability to find a donor. That said, which path is actually feasible depends on the type of disease, age, and urgency of treatment, so individual case review is necessary.

FAQ — What If No Family Member Can Be a Donor?

The search proceeds in order: siblings, haploidentical family (parents/children), unrelated donors, and cord blood. Even without a fully matched family member, allogeneic transplant can still be arranged through an unrelated donor or cord blood, and which path applies depends on the type of disease and urgency. Determining exactly which path is possible requires evaluation based on the patient's condition and test results.

Sources and Notes

• This article was written based on hematopoietic stem cell transplant and blood cancer resources (National Cancer Center Korea, NCCN patient guidelines, Medical Korea, and HiKorea).
• This content is intended for general medical information purposes only, and diagnosis, treatment methods, and outcomes may vary depending on individual conditions. Accurate diagnosis and treatment should always be determined through consultation with a medical professional.